Market Data
Market Cap₹38,730.77 Cr.
52W High₹2,509.4
Current Price₹2,412.25
52W Low₹1,603.05
Down from 52W High3.9 %
Face Value₹1
Performance
ROCE23.03 %
ROE17.06 %
EPS (TTM)₹6.35
EPS Prev Qtr₹12.63
EPS Last Year₹12.99
EBITDA Qtr₹151.12 Cr.
Book Value₹259
Financial Health
Debt/Equity0
Debt/Profit0
Total Assets₹4,968.647 Cr.
Dividend Yield0.39 %
Promoter Holding48.8 %
Earning Power18.62 %
Valuation
Stock P/E53.3
Industry P/E33.81
Price to Book9.31
Price to Sales9.34
Graham Number₹513.67
Key Metrics
Face Value
₹1
About J B Chemicals & Pharmaceuticals Ltd
Healthcare · Pharmaceuticals
J B Chemicals & Pharmaceuticals Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹1. Market cap ₹38,730.77 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a strong ROCE of 23.03%, indicating efficient use of capital.
- The company boasts a healthy ROE of 17.06%, reflecting strong profitability relative to shareholder equity.
- The company is debt-free with a Debt to Equity ratio of 0, reducing financial risk.
- The company has a significant promoter holding of 48.8%, suggesting strong management control and alignment of interests.
Weaknesses
- The P/E ratio of 53.3 indicates that the stock may be overvalued relative to its earnings.
- The P/B ratio of 9.31 suggests that the market values the company at a premium compared to its book value.
- The dividend yield is low at 0.39%, which may not attract income-focused investors.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 1,093.94 | 1,084.9 | 1,064.72 | 904.23 |
| ↳ QoQ Growth | - | -0.8% | -1.9% | -15.1% |
| Expenses | 835.77 | 819.74 | 814.25 | 753.11 |
| Operating Profit | 258.17 | 265.16 | 250.47 | 151.12 |
| OPM % | 23.6% | 24.44% | 23.52% | 16.71% |
| Other Income | 14.55 | 15.34 | 18.28 | 11.98 |
| Interest | 1.11 | 1.35 | 1.88 | 1.23 |
| Depreciation | 42.7 | 44.44 | 45.35 | 50.01 |
| EBITDA | 300.87 | 309.6 | 295.82 | 201.13 |
| EBITDA Margin % | 27.5% | 28.54% | 27.78% | 22.24% |
| Profit Before Tax | 271.61 | 279.15 | 266.87 | 134.69 |
| Tax % | 25.49% | 25.55% | 25.85% | 24.74% |
| Net Profit | 202.38 | 207.82 | 197.89 | 101.37 |
| ↳ QoQ Growth | - | +2.7% | -4.8% | -48.8% |
| EPS | 12.99 | 13.29 | 12.63 | 6.35 |
Profit & Loss
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 4147.79 | 4147.79 |
| Expenses | 3222.87 | 3222.87 |
| Operating Profit | 924.92 | 924.92 |
| OPM % | 22.3% | 22.3% |
| Other Income | 60.15 | 60.15 |
| Interest | 5.57 | 5.57 |
| Depreciation | 182.5 | 182.5 |
| Profit Before Tax | 952.32 | 952.32 |
| Tax % | 25.5% | 25.5% |
| Net Profit | 709.46 | 709.46 |
| EPS | 45.26 | 45.26 |
Compounded Sales Growth
10Y
-
5Y
-
3Y
-
TTM
-
Compounded Profit Growth
10Y
-
5Y
-
3Y
-
TTM
-
Stock Price CAGR
10Y
-
5Y
-
3Y
-
1Y
41.05%
Return on Equity
10Y
-
5Y
-
3Y
-
Last Year
17.06%
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 15.57 | 16.0559 |
| Reserves | 3417.75 | 4143.164 |
| Borrowings | 21.53 | 0 |
| Other Liabilities | 818.93 | 809.43 |
| Total Liabilities | 4273.78 | 4968.6465 |
| Fixed Assets | 609.94 | 1898.182 |
| CWIP | 46.7 | 61.1639 |
| Investments | 345.09 | 764.93 |
| Other Assets | 3272.05 | 2244.37 |
| Total Assets | 4273.78 | 4968.6465 |
Cash Flows
| Mar 2026 | |
|---|---|
| Cash from Operating Activity | 703.9199 |
| Cash from Investing Activity | -585.8777 |
| Cash from Financing Activity | -123.0969 |
| Net Cash Flow | -5.0547 |
Ratios
| Mar 2026 | |
|---|---|
| Debtor Days | - |
| Inventory Days | - |
| Days Payable | - |
| Cash Conversion Cycle | - |
| Working Capital Days | 437.23 |
| ROCE % | 18.62% |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|
| Promoters % | 47.56% | 47.55% | 48.8% |
| FIIs % | 15.3% | 14.88% | 16.33% |
| DIIs % | 22.83% | 23.35% | 21.39% |
| Public % | 12.47% | 12.37% | 11.77% |
| No. of Shareholders | 71,957 | 69,338 | 74,043 |
Major Shareholders (>1%)
- Torrent Pharmaceuticals LimitedPromoter and Promoter Group48.80%
- Kotak Midcap FundPublic Shareholding4.40%
- Axis Mutual Fund Trustee Limited A/c Axis Mutual Fund A/c Axis Small Cap FundPublic Shareholding3.81%
- Canara Robeco Mutual Fund A/c Canara Robeco Small Cap FundPublic Shareholding2.17%
As of 2026-03-31View all shareholders →